Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
January 20, 2025
-
BUSINESS Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
-
REGULATORY 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums
January 16, 2025
-
REGULATORY Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister
January 15, 2025
-
BUSINESS SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
January 14, 2025
-
BUSINESS Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
-
COMMENTARY Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
January 9, 2025
-
ORGANIZATION Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
January 9, 2025
-
REGULATORY MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
-
BUSINESS Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
-
ORGANIZATION 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
January 7, 2025
-
ORGANIZATION As 2025 Begins, Industry Leaders Renew Resolve towards Next Reforms
January 6, 2025
-
REGULATORY Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
-
REGULATORY Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
-
REGULATORY Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
-
TRENDS Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
-
REGULATORY Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
-
REGULATORY CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
-
COMMENTARY Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
REGULATORY Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…